Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 3, May-June, p. 369–375

Publication type: original article

Language: English

An Analysis of the Impact of Clinico-Pathological Features on Long-Term Results Following Esophagectomy Due to Squamous Cell Carcinoma of the Thoracic Esophagus

Analiza wpływu wybranych cech kliniczno-patologicznych na wynik odległy w grupie chorych poddanych resekcji przełyku piersiowego z powodu płaskonabłonkowego raka

Barbara Śliwa1,A,B,C, Piotr Szelachowski1,A,C,D, Marta Strutyńska-Karpińska1,E,F

1 Department and clinic of Gastrointestinal and General Surgery of Wroclaw Medical University, Poland

Abstract

Background. Squamous cell carcinoma of the esophagus is one of the neoplasms characterized by an exceptionally latent course, dynamic development and poor prognosis. The stage of the disease at the time of treatment is started the greatest impact on the long term results.
Objectives. The aim of this study was to evaluate selected clinical-pathological features as prognostic factors for long term survival among patients who have undergone esophagectomies due to squamous cell carcinoma. The features analyzed were age, gender, the stage of the disease and the type of tumor. Long-term survival rates (2, 5 and 10 years) were analyzed in relation to the particular features.
Material and Methods. The study group consisted of 65 patients diagnosed with squamous cell carcinoma of the thoracic esophagus who underwent esophagectomies between 1997 and 2008. The statistical analysis was performed with Statistca 8.0 software. Gehan-Wilcoxon, chi and Kaplan-Meier tests were carried out.
Results. The research did not find any statistically significant correlation between the patients’ gender and survival time (Gehan-Wilcoxon p = 0.83; log-rank p = 0.86). The results showed no statistically significant correlation between the patients’ age and survival time (Gehan-Wilcoxon p = 0.75; log-rank p = 0.47). The only statistically significant impact of the stage of the disease on the survival time was a correlation between the longer survival time and the stage I and II of the disease (chi p = 0.15). The log-rank test revealed that survival time is significantly shorter in cases of involved nodes (Gehan-Wilcoxon p = 0.054; log-rank p = 0.014).
Conclusion. among the clinical-pathological features investigated, only metastases in regional lymph nodes had any significant impact on long-term survival.

Streszczenie

Wprowadzenie. Płaskonabłonkowy rak przełyku jest zaliczany do nowotworów o wyjątkowo skrytym przebiegu, dużej dynamice rozwoju i skrajnie niekorzystnym rokowaniu. faktem jest, że stopień zaawansowania raka przełyku w chwili podjęcia leczenia operacyjnego ma decydujący wpływ na wynik odległy.
Cel pracy. Ocena wybranych cech kliniczno-patologicznych jako czynnika prognostycznego przeżyć odległych w grupie chorych po resekcji przełyku z powodu raka płaskonabłonkowego. analizie poddano takie cechy jak: wiek i płeć, stopień zaawansowania i zróżnicowania raka oraz prześledzono współzależność przeżyć odległych (2-, 5- i 10-letnich) w odniesieniu do poszczególnych cech.
Materiał i metody. Badana grupa obejmowała 65 pacjentów z rozpoznanym płaskonabłonkowym rakiem piersiowego odcinka przełyku, którzy w latach 1997–2008 byli poddani operacji resekcyjnej. Wykorzystano następujące testy statystyczne: Statistica 8.0, Gehan-Wilcoxon, chi, Kaplan-Meier.
Wyniki. Wykazano brak istotnej statystycznie korelacji między płcią a czasem przeżycia (Gehan-Wilcoxon p = 0,83; log-rank p = 0,86). Wykazano brak istotnej statystycznie korelacji między wiekiem pacjenta a czasem przeżycia. (Gehan-Wilcoxon p = 0,75; log-rank p = 0,47). Nie wykazano istotnego statystycznie wpływu stopnia zaawansowania na długość przeżycia, niemniej jednak wyraźnie wykazano korelację między wydłużonym czasem przeżycia a stopniem zaawansowania 1 i 2 (chi p = 0,15). Za pomocą testu log-rank wykazano istotną statystycznie zależność – zajęcie przez komórki nowotworowe węzłów chłonnych skraca czas przeżycia (Gehan-Wilcoxon p = 0,054; logrank p = 0,014).
Wnioski. Biorąc pod uwagę cechy kliniczno-patologiczne wykazano, że jedynie cecha N miała istotny wpływ na wynik odległy.

Key words

squamous cell carcinoma of the esophagus, esophagectomy, prognostic factor of long-term survival.

Słowa kluczowe

płaskonabłonkowy rak przełyku, resekcja przełyku, czynnik prognostyczny przeżyć odległych.

References (35)

  1. Holmes RS, Vaughan TL: epidemiology and pathogenesis of esophageal cancer. Semin radiat Oncol 2007, 17(1), 2–9.
  2. Xu XC: risk factors and gene expression in esophageal cancer. Meth Mol Biol 2009, 471, 335–360.
  3. Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakayiama T, Kuwano H: cd24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. ann Surg Oncol 2009, 16(2), 506–514.
  4. Siewert JR, Feith M, Stein HJ: esophagectomy as therapeutic principle for squamous cell cancer. chirurg 2005, 76(11), 1033–1043.
  5. Sato M, Ando N: Standard radical esophagectomy in thoracic esophageal cancer. Nippon Geka Gakkai Zasshi 2008, 109(1), 21–25.
  6. Boone J, Livestro DP, Elias SG, Borel Rinkes IH, van Hillegersberg R: International survey on esophageal cancer: part I surgical techniques. dis esophagus 2009 Jan 23. [epub ahead of print].
  7. Li H, Zhang Y, Cai H, Xiang J: Pattern of lymph node matastases in patients with squamous cell carcinoma of the thoracic esophagus who underwent three-field lymphadenectomy. eur Surg res 2007, 39(1), 1–6.
  8. Gotohda N, Nishimura M, Yoshida J, Nagai K, Tanaka N: The pattern of lymphatic metastases in superficial squamous cell carcinoma of the esophagus. Hepatogastroenterology 2005, 52(61), 105–107.
  9. Lee J, Lee KE, Im Yh, Kang WK, Park K, Kim K, Shim YM: adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. ann Thorac Surg 2005, 80(4), 1170–1175.
  10. Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007, 8(6), 545–553.
  11. Hartwig W, Strobel O, Lordick F, Büchler MW, Werner J: Multimodal therapy of esophageal cancer. Z Gastroenterol 2008, 46(10), 1207–1213.
  12. Matsubara H: Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J clin Oncol 2008, 13(6), 474–478.
  13. Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y, Shimada H: Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg 2008, 12(5), 802–810.
  14. Kunisaki C, Makino H, Oshima T, Fujii S, Takagawa R, Kimura J, Kosaka T, Ono HA, Akiyama H: clinicopathological features in N0 oesophageal cancer patients. endo I anticancer res 2010, 30(7), 3063–3069.
  15. Zhang HL, Liu RL, Shi YT, Wang ZC, Wang BH, Li YJ, Zhou LY, Ping YM: analysis of the survival in patients after surgical resection of thoracic esophageal cancer. Zhonghua Zhong Liu Za Zhi 2009, 31(7), 541–545.
  16. Tachibana M, Dhar DK, Kinugasa S, Kotoh T, Shibakita M, Ohno S, Masunaga R, Kubota H, Nagasue N:esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. J clin Gastroenterol 2000, 31(4), 318–322.
  17. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Shimada H: developing an appropriate staging system for esophageal carcinoma. J am coll Surg 2005, 201(6), 884–890.
  18. Zhang H, Ping Y, Du X: Study on factors influencing survival in patients with cancer of the esophagus after resection by cox proportional hazard model. Zhonghua Zhong Liu Za Zhi 1999, 21(1), 32–34.
  19. Dhar DK, Tachibana M, Kinukawa N, Riruke M, Kohno H, Little AG, Nagasue N: The prognostic significance of lymph node size in patients with squamous esophageal cancer. ann Surg Oncol 2002, 9(10), 1010–1016.
  20. Komori T, Doki Y, Kabuto T, Ishikawa O, Hiratsuka M, Sasaki Y, Ohigashi H, Murata K, Yamada T, Miyashiro I, Mano M, Ishiguro S, Imaoka S: Prognostic significance of the size of cancer nests in metastatic lymph nodes in human esophageal cancers. J Surg Oncol 2003, 82(1), 19–27.
  21. Hosch S, Kraus J, Scheunemann P, Izbicki JR, Schneider C, Schumacher U, Witter K, Speicher MR, Pantel K: Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. cancer res 2000, 15,60(24), 6836–6840.
  22. Li SH, Wang Z, Liu XY, Liu FY, Sun ZY, Xue H: Lymph node micrometastasis: a predictor of early tumor relapse after complete resection of histologically node-negative esophageal cancer. Surg Today 2007,37(12), 1047–1052.
  23. Shimada H, Okazumi S, Shiratori T, Akutsu Y, Matsubara H: Impact of lymph node involvement in T2 or T3 thoracic esophageal squamous cell carcinoma. Hepatogastroenterology 2009,56(93), 1039–1043.
  24. Kunisaki C, Makino H, Kimura J, Oshima T, Fujii S, Takagawa R, Kosaka T, Ono HA, Akiyama H: Impact of lymph-node metastasis site in patients with thoracic esophageal cancer. J Surg Oncol 2010, 101(1), 36–42.
  25. Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC: Tumor length as a prognostic factor in esophageal squamous cell carcinoma. ann Thorac Surg 2011, 91(3), 887–893.
  26. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Watson TJ, Swisher SG: endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer; M.d. anderson esophageal cancer Group; University of rochester School of Medicine and dentistry foregut Group. cancer 2011, 117(1), 63–69. doi: 10.1002/cncr.25373.
  27. Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM: Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol 2006, 93(4), 258–267.
  28. Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A: defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy. ann Surg Oncol 2011, 18(6), 1766–1774.
  29. Zhang DK, Su XD, Long H, Lin P, Fu JH, Zhang LJ, Ma GW, Zhu ZH, Dai Y, Rong TH: Surgical treatment and prognosis in patients with squamous cell carcinoma of thoracic esophagus. Zhonghua Wai Ke Za Zhi 2008, 46(17), 1333–1336.
  30. Hu Y, Zheng B, Rong TH, Fu JH, Zhu ZH, Yang H, Luo KJ, Li YF: Prognostic analysis of the patients with stageIII esophageal squamous cell carcinoma after radical esophagectomy. chin J cancer 2010, 29(2), 178–183.
  31. Kolh P, Honore P, Gielen JL, Degauque C, Azzam C, Legrand M, Jacquet N: analysis of factors influencing long-term survival after surgical resection for oesophageal squamous cell carcinoma. acta chir Belg 1999, 99(3), 113–118.
  32. Yuequan J, Shifeng C, Bing Z: Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. ann Thorac Surg 2010, 90(3), 908–913.
  33. Hamouda A, Forshaw M, Rohatgi A, Mirnezami R, Botha A, Mason R: Presentation and survival of operable esophageal cancer in patients 55 years of age and below. World J Surg 2010, 34(4), 744–749.
  34. Tachibana M, Kinugasa S, Dhar DK, Shibakita M, Ohno S, Masunaga R, Kotoh T, Kubota H, Nagasue N: Prognostic factors in node-negative squamous cell carcinoma of the thoracic esophagus. Int J Surg Invest 2000, 1(5), 389–395.
  35. Neuhof D, Neumayer F, Einbeck W, Haschemian K, Mai SK, Hochhaus A, Willeke F, Rudi J, Debus J, Wenz F: retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. acta Oncol 2005, 44(2), 168–173.
© Wroclaw Medical University